Epigral Ltd. (EPIGRAL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Epigral Ltd. (EPIGRAL) has a cash flow conversion efficiency ratio of 0.127x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Rs2.67 Billion ≈ $28.91 Million USD) by net assets (Rs21.01 Billion ≈ $227.23 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See Epigral Ltd. defensive liquidity buffer to measure how many days the company can operate on defensive assets alone.
Epigral Ltd. - Cash Flow Conversion Efficiency Trend (2015–2026)
This chart illustrates how Epigral Ltd.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Epigral Ltd. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Epigral Ltd. ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Societe de la Tour Eiffel SA
PA:EIFF
|
0.036x |
|
Wuxi Jinyang New Materials Co. Ltd. A
SHE:301210
|
N/A |
|
Neuropace Inc
NASDAQ:NPCE
|
-0.408x |
|
Solus Advanced Materials Co Ltd
KO:336370
|
0.006x |
|
Beijing Hualian Department Store Co Ltd
SHE:000882
|
0.029x |
|
Shanghai Yahong Moulding Co Ltd
SHG:603159
|
0.056x |
|
Jiangsu United Water Technology Co. Ltd. Cl A
SHG:603291
|
N/A |
|
Invesco Quality Municipal Income Closed Fund
NYSE:IQI
|
0.018x |
Annual Cash Flow Conversion Efficiency for Epigral Ltd. (2015–2026)
The table below shows the annual cash flow conversion efficiency of Epigral Ltd. from 2015 to 2026. For the full company profile with market capitalisation and key ratios, see market cap of Epigral Ltd..
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2026-03-31 | Rs22.21 Billion ≈ $240.24 Million |
Rs3.88 Billion ≈ $41.92 Million |
0.174x | -24.57% |
| 2025-03-31 | Rs19.05 Billion ≈ $205.97 Million |
Rs4.41 Billion ≈ $47.64 Million |
0.231x | -27.04% |
| 2024-03-31 | Rs12.54 Billion ≈ $135.63 Million |
Rs3.98 Billion ≈ $43.00 Million |
0.317x | -45.86% |
| 2023-03-31 | Rs10.69 Billion ≈ $115.62 Million |
Rs6.26 Billion ≈ $67.72 Million |
0.586x | +49.81% |
| 2022-03-31 | Rs7.26 Billion ≈ $78.51 Million |
Rs2.84 Billion ≈ $30.69 Million |
0.391x | +16.69% |
| 2021-03-31 | Rs6.84 Billion ≈ $73.99 Million |
Rs2.29 Billion ≈ $24.79 Million |
0.335x | +18.71% |
| 2020-03-31 | Rs5.83 Billion ≈ $63.10 Million |
Rs1.65 Billion ≈ $17.81 Million |
0.282x | -46.78% |
| 2019-03-31 | Rs4.93 Billion ≈ $53.29 Million |
Rs2.61 Billion ≈ $28.26 Million |
0.530x | +22.00% |
| 2018-03-31 | Rs5.17 Billion ≈ $55.95 Million |
Rs2.25 Billion ≈ $24.32 Million |
0.435x | +13.58% |
| 2017-03-31 | Rs3.62 Billion ≈ $39.12 Million |
Rs1.38 Billion ≈ $14.97 Million |
0.383x | -8.46% |
| 2016-03-31 | Rs2.95 Billion ≈ $31.92 Million |
Rs1.23 Billion ≈ $13.35 Million |
0.418x | -17.91% |
| 2015-03-31 | Rs2.20 Billion ≈ $23.82 Million |
Rs1.12 Billion ≈ $12.13 Million |
0.509x | -- |
About Epigral Ltd.
Epigral Limited manufactures and sells chlor-alkali and derivative products in India and internationally. The company offers chlorinated polyvinyl chloride (CPVC) resin, epichlorohydrin, chloromethanes value chain, hydrogen peroxide, caustic soda and potash, chlorine, hydrogen, chloromethanes, captive power plant (CPP), and chlorotoluene value chain, as well as operates wind-solar hybrid power pl… Read more